GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (NAS:GILD) » Definitions » 50-Day SMA

Gilead Sciences (Gilead Sciences) 50-Day SMA : $71.28 (As of Apr. 27, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Gilead Sciences 50-Day SMA?

Moving averages are one of the core indicators in technical analysis. A Simple Moving Average (SMA) is simply the arithmetic average of stock price over a period. It is calculated by adding a selected range of prices, usually closing prices, and then dividing that figure by the number of time periods in that range.

The 50-Day SMA calculates the average price over 50 days. And the 20-Day SMA and 200-Day SMA calculates the average price over 20 days and 200 days separately.

As of today (2024-04-27), Gilead Sciences's 50-Day SMA is $71.28. It's 20-Day SMA is $68.29 and 200-Day SMA is $76.36.


Competitive Comparison of Gilead Sciences's 50-Day SMA

For the Drug Manufacturers - General subindustry, Gilead Sciences's 50-Day SMA, along with its competitors' market caps and 50-Day SMA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's 50-Day SMA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's 50-Day SMA distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's 50-Day SMA falls into.



Gilead Sciences  (NAS:GILD) 50-Day SMA Calculation

The formula for calculating SMA is:

SMA=( P1 + P2 + ... + Pn ) / n

where:
Pn is the price of the stock at period n.
n is the total number of periods.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gilead Sciences  (NAS:GILD) 50-Day SMA Explanation

Simple Moving Average (SMA) is the arithmetic average of stock price over a period. The 20-Day SMA calculates the average price over 20 days. And the 50-Day SMA and 200-Day SMA calculates the average price over 50 days and 200 days separately. SMAs are often used to determine the price trend direction. A 200-Day SMA is usually a proxy for the long-term trend, while shorter periods indicate short-term trend.

SMA are commonly compared with stock price or different period SMAs to indicate a trading signal. Generally speaking, if the price goes above the SMA, or a short-term SMA crosses above a long-term SMA, an uptrend is expected, investors may want to go long or cover short. Conversely, if the price goes below the SMA, or the short-term SMA crosses below a long-term SMA, a downtrend is expected, investors may want to go short or exit long.

Two popular trading patterns that use SMA include the death cross and a golden cross. A death cross occurs when the 50-day SMA crosses below the 200-day SMA. This is considered a bearish signal, that further losses are in store. The golden cross is a bullish signal which occurs when a short-term SMA crosses above a long-term SMA.


Gilead Sciences 50-Day SMA Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's 50-Day SMA provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences (Gilead Sciences) Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Executives
Andrew D Dickinson officer: EVP, Chief Financial Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Johanna Mercier officer: Chief Commercial Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Merdad Parsey officer: Chief Medical Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Patterson officer: SVP, Controllership 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Diane E. Wilfong officer: SVP, Controller & CAO 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Deborah H Telman officer: EVP, Corporate Affairs & GC 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Brett A Pletcher officer: EVP, Gen Counsel & Corp Sec 333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Jeffrey Bluestone director C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858
Anthony Welters director
Javier Rodriguez director 601 HAWAII ST., EL SEGUNDO CA 90245
John Francis Cogan director 2010 NORTH FIRST STREET, SUITE 310, SAN JOSE CA 95131
Gayle E Wilson director C/O GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Olsen Per Wold director C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Horning director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Richard James Whitley director UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711